Work

An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.8039

Authors: Tom Stinchcombe, Lynette M. Sholl, Xiaofei F. Wang, Lin Gu, Mark A. Socinski, Scott J. Rodig, Marzia Capelletti, Jeffrey Crawford, Martin J. Edelman, Miguel Angel Villalona-Calero, Robert Arthur Kratzke, Everett E. Vokes, Vincent A. Miller, Pasi Antero Janne, Alliance

Institutions: University of North Carolina at Chapel Hill, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, University of Pittsburgh Medical Center, Harvard University, Duke Medical Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, University of Minnesota, University of Chicago, Foundation Medicine (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2598035832

Cites:

Cited by:

Related to: 10